Related Experiment Videos
Rapamycin inhibits proteasome activator expression and proteasome activity
1Laboratory of Transplantation Immunology, Louis-Charles Simard Research Center, Montreal, Canada.
European Journal of Immunology
|December 12, 1997
Summary
Rapamycin (RAPA) affects immune responses by targeting proteasome activators. This study identifies PA28 alpha and beta subunits as key RAPA targets, modulating proteasome activity in activated immune cells.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Rapamycin (RAPA) is an immunosuppressive drug with incompletely understood mechanisms.
- Immune response regulation involves complex molecular pathways.
- Proteasomes play a critical role in degrading regulatory proteins.
Purpose of the Study:
- To identify human genes sensitive to RAPA using differential hybridization.
- To investigate the role of RAPA-sensitive genes in immune cell activation.
- To determine if proteasome activators are downstream targets of RAPA.
Main Methods:
- Differential hybridization to screen for RAPA-sensitive genes.
- Quantitative analysis of PA28 alpha and beta mRNA expression in activated T and B cells.
- Immunoblotting and confocal microscopy to assess protein levels.
- Measurement of proteasome activity in peripheral blood mononuclear cells.
Main Results:
- Seven RAPA-sensitive genes were identified, including one encoding PA28 beta.
- PA28 beta mRNA was upregulated in activated T and B cells, suppressed by RAPA, FK506, and cyclosporin A.
- RAPA and FK506 repressed PA28 alpha mRNA in PHA-stimulated T cells.
- RAPA inhibited PA28 alpha and beta protein expression and reduced enhanced proteasome activity in activated T cells.
Conclusions:
- The proteasome activator (PA28 alpha and beta) is a relevant downstream target of rapamycin.
- Modulation of proteasome activity by RAPA offers a potential mechanism for regulating immune responses.
- Targeting proteasome activators may represent a novel strategy for immunosuppression.